[Restrictive cardiomyopathy associated with heart failure].
Konno
Tetsuo
T
Department of Internal Medicine, Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine.
Ino
Hidekazu
H
Fujino
Noboru
N
Hayashi
Kenshi
K
Yamagishi
Masakazu
M
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002313:Cardiomyopathy, Restrictive / Q000150:complications / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D003952:Diagnostic Imaging; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D009154:Mutation; D011379:Prognosis; D019210:Troponin I / Q000235:genetics; D024723:Ventricular Myosins / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D004232:Diuretics; D019210:Troponin I; D024723:Ventricular Myosins